CureVac (CVAC) Competitors $5.37 0.00 (0.00%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$5.38 +0.00 (+0.09%) As of 08/29/2025 06:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CVAC vs. TGTX, CYTK, AAPG, KRYS, ACAD, ADMA, TLX, PCVX, PTCT, and LNTHShould you be buying CureVac stock or one of its competitors? The main competitors of CureVac include TG Therapeutics (TGTX), Cytokinetics (CYTK), Ascentage Pharma Group International (AAPG), Krystal Biotech (KRYS), ACADIA Pharmaceuticals (ACAD), ADMA Biologics (ADMA), Telix Pharmaceuticals (TLX), Vaxcyte (PCVX), PTC Therapeutics (PTCT), and Lantheus (LNTH). These companies are all part of the "pharmaceutical products" industry. CureVac vs. Its Competitors TG Therapeutics Cytokinetics Ascentage Pharma Group International Krystal Biotech ACADIA Pharmaceuticals ADMA Biologics Telix Pharmaceuticals Vaxcyte PTC Therapeutics Lantheus CureVac (NASDAQ:CVAC) and TG Therapeutics (NASDAQ:TGTX) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, media sentiment, profitability, dividends, earnings and analyst recommendations. Do institutionals & insiders hold more shares of CVAC or TGTX? 17.3% of CureVac shares are owned by institutional investors. Comparatively, 58.6% of TG Therapeutics shares are owned by institutional investors. 10.6% of TG Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Do analysts rate CVAC or TGTX? CureVac currently has a consensus target price of $6.83, suggesting a potential upside of 27.25%. TG Therapeutics has a consensus target price of $46.25, suggesting a potential upside of 57.69%. Given TG Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe TG Therapeutics is more favorable than CureVac.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CureVac 0 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.20TG Therapeutics 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 Is CVAC or TGTX more profitable? CureVac has a net margin of 38.21% compared to TG Therapeutics' net margin of 13.31%. CureVac's return on equity of 29.57% beat TG Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets CureVac38.21% 29.57% 25.41% TG Therapeutics 13.31%26.05%9.58% Does the media refer more to CVAC or TGTX? In the previous week, TG Therapeutics had 4 more articles in the media than CureVac. MarketBeat recorded 7 mentions for TG Therapeutics and 3 mentions for CureVac. TG Therapeutics' average media sentiment score of 1.58 beat CureVac's score of 1.09 indicating that TG Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CureVac 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive TG Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Which has more risk & volatility, CVAC or TGTX? CureVac has a beta of 2.53, meaning that its share price is 153% more volatile than the S&P 500. Comparatively, TG Therapeutics has a beta of 1.88, meaning that its share price is 88% more volatile than the S&P 500. Which has better valuation & earnings, CVAC or TGTX? CureVac has higher revenue and earnings than TG Therapeutics. CureVac is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCureVac$579.18M2.08$175.50M$0.965.59TG Therapeutics$329M14.15$23.38M$0.3779.27 SummaryTG Therapeutics beats CureVac on 9 of the 16 factors compared between the two stocks. Get CureVac News Delivered to You Automatically Sign up to receive the latest news and ratings for CVAC and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CVAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CVAC vs. The Competition Export to ExcelMetricCureVacMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.20B$3.07B$5.75B$9.76BDividend YieldN/A2.29%4.08%4.04%P/E Ratio5.5920.7883.2726.60Price / Sales2.08386.53541.17113.73Price / Cash6.1544.2237.4459.26Price / Book1.608.0710.556.58Net Income$175.50M-$53.98M$3.27B$265.95M7 Day Performance-1.29%-0.88%0.40%0.17%1 Month Performance-0.37%7.72%7.31%3.90%1 Year Performance71.02%7.03%46.58%19.67% CureVac Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CVACCureVac4.3435 of 5 stars$5.37flat$6.83+27.3%+71.0%$1.20B$579.18M5.59880Positive NewsTGTXTG Therapeutics4.6557 of 5 stars$28.53-3.1%$46.25+62.1%+24.9%$4.67B$329M77.11290Positive NewsCYTKCytokinetics3.6688 of 5 stars$37.01-3.5%$71.58+93.4%-38.1%$4.59B$18.47M-7.26250News CoverageAAPGAscentage Pharma Group InternationalN/A$43.48-9.2%N/AN/A$4.45B$134.35M0.00600Gap UpHigh Trading VolumeKRYSKrystal Biotech4.7212 of 5 stars$146.77-2.5%$210.38+43.3%-24.3%$4.36B$290.52M29.83210ACADACADIA Pharmaceuticals3.776 of 5 stars$25.32-1.6%$28.88+14.0%+56.8%$4.34B$957.80M19.04510Positive NewsAnalyst RevisionADMAADMA Biologics4.2734 of 5 stars$17.01-4.4%$27.67+62.6%-0.3%$4.25B$426.45M19.78530Positive NewsTLXTelix PharmaceuticalsN/A$12.20-2.2%$22.33+83.1%N/A$4.22B$516.72M0.00N/ATrending NewsAnalyst ForecastAnalyst RevisionGap DownPCVXVaxcyte2.3832 of 5 stars$30.45-5.7%$136.50+348.3%-61.9%$4.19BN/A0.00160News CoveragePositive NewsPTCTPTC Therapeutics4.3529 of 5 stars$49.30-2.5%$69.15+40.3%+39.7%$4.02B$806.78M7.071,410Positive NewsLNTHLantheus4.7347 of 5 stars$56.16-3.5%$105.50+87.9%-48.4%$3.96B$1.53B14.94700Positive News Related Companies and Tools Related Companies TGTX Competitors CYTK Competitors AAPG Competitors KRYS Competitors ACAD Competitors ADMA Competitors TLX Competitors PCVX Competitors PTCT Competitors LNTH Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CVAC) was last updated on 8/31/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CureVac N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share CureVac With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CVAC Stock Alerts